TJ Biopharma Co., Ltd.
Clinical trials sponsored by TJ Biopharma Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug targets Life-Threatening immune storm in rheumatic patients Results expected Dec 2026 (estimated)
-
New drug cocktail aims to stall lung cancer
Disease control OngoingThis study tests whether adding a new drug called uliledlimab to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer live longer without their disease getting worse. About 150 adults who have not had prior treatment for their advanced …
Phase 2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail aims to outperform standard lung cancer therapy
Disease control OngoingThis study tests whether a new drug combination (uliledlimab plus toripalimab) works better than the standard immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that hasn't been treated yet. The trial includes 450 participants whose tumors have specif…
Phase 2/3 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC